DCGO DocGo Inc. Insider Trading

DCGO Director Burdiek buys 10,000 shares at $1.33 amid -76.1% 52-week decline; stock down -38.0% in 30 days.

Michael J Burdiek, a Director, purchased 10,000 shares of DocGo Inc. (DCGO) at $1.33 on 2025-05-23, increasing his holdings to 641.6K shares. The purchase occurs in a severely distressed price environment: the stock trades -76.1% below its 52-week high of $5.60 and has fallen -38.0% over the past 30 days and -72.0% over 90 days. Burdiek's cross-ticker track record shows 3 prior buys with an average 90-day return of -7.7% and a 0% win rate, while his same-ticker history at DCGO (2 measurable prior buys) posted 90-day returns of -2.6% and -12.7%, with 0 of 2 trades well-timed at the 90-day mark. Additionally, 4 other insiders bought DCGO within the past 14 days, forming a cluster buy pattern, though the fundamental picture remains mixed: the company reported -$11.1M net income on $96.0M quarterly revenue with -1.2% annual revenue growth. The repetitive purchasing despite consistent negative returns and sharp recent price declines warrants close examination of the underlying business trajectory and insider motivations.

Director Burdiek buys 15,000 shares of DCGO at $1.43; stock down -75.0% from 52-week high of $5.60.

Burdiek Michael J, a Director at DocGo Inc., purchased 15,000 shares at $1.43 on 2025-05-15, increasing his holdings to 631,560 shares. The purchase occurs in a heavily distressed context: the stock trades at $1.40 (current price), down -75.0% from its 52-week high of $5.60, and has declined -37.8% over the past 30 days and -74.7% over the past 90 days. His prior two buys at DCGO (May 2024 and March 2024) both produced negative 90-day returns (-2.6% and -12.7%), with neither proving well-timed. A cluster of 4 other insiders also bought within the past 14 days, suggesting coordinated accumulation during depressed pricing. Fundamentally, the company reported net income of $-11.1M on revenue of $96.0M, with annual revenue declining -1.2% year-over-year and a P/E of 7.00, indicating financial stress underlying the stock's collapse.

Director Klasko purchases 15,000 shares at $1.49; stock down -75.0% from 52-week high amid cluster buy by 3 other insiders in 14 days

Klasko Stephen K. M.D., a Director, acquired 15,000 shares at $1.49 on 2025-05-14, representing an initial equity stake with zero prior holdings. This purchase occurs during a marked downturn: the stock is trading at $1.40, down -75.0% from its 52-week high of $5.60 and down -74.8% over 90 days. The broader context shows a cluster pattern—3 other insiders also bought within the past 14 days—suggesting coordinated conviction among leadership during a sharp price decline. DocGo's fundamentals remain challenged: the company posted a net loss of $-11.1M in its latest quarter and has experienced -1.2% annual revenue growth, though it maintains a market cap of $138.7M. The simultaneous insider accumulation at depressed price levels following extreme drawdown deserves careful examination of whether this reflects genuine business recovery confidence or represents contrarian positioning under duress.

CFO Norman Rosenberg buys 15,000 DCGO shares at $1.47; stock down 75.0% from 52-week high, amid cluster buying by 3 other insiders.

Norman Rosenberg, CFO and Treasurer, purchased 15,000 shares at $1.47 on 2025-05-14, expanding his holdings by 1.8% to 871,272 shares total. The transaction occurs against a backdrop of severe stock deterioration: DCGO is trading at $1.40, down 75.0% from its 52-week high of $5.60 and has declined 40.4% over the past 30 days. Rosenberg's cross-ticker track record shows 1 prior buy with an average 90-day return of -12.7%, and his same-ticker trade at DCGO in March 2024 produced a -12.7% 90-day return. Notably, 3 other insiders also bought DCGO within the past 14 days, forming a cluster purchase pattern. The company's fundamentals remain challenged: latest quarterly revenue is $96.0M, with a net loss of $-11.1M and negative annual growth of -1.2%.

CEO Bienstock Lee buys 15,000 shares of DCGO at $1.54; stock down -75.0% from 52-week high of $5.60, cluster of 3 other insiders also bought within 14 days.

CEO Bienstock Lee purchased 15,000 shares at $1.54 on 2025-05-14, expanding his holdings to 1,971,079 shares. The transaction occurs at a significant discount to the 52-week high of $5.60 (stock currently trading at $1.40, down 75.0% from peak). The company reports negative net income of $-11,079,300.00 against revenue of $96,033,055.00, with annual revenue growth of -1.2%. Notably, three other insiders also made purchases within the same 14-day window, suggesting coordinated confidence at depressed valuations. The CEO's prior trade at this ticker (May 2024 buy) was well-timed with a +12.4% 90-day return, establishing a pattern of timing purchases around market dislocations at DCGO.

Chief Compliance Officer Stephen Sugrue buys 10,000 shares of DCGO at $1.44 as stock down -75.0% from 52-week high; cluster of 3 other insiders also bought.

Stephen Sugrue, Chief Compliance Officer, purchased 10,000 shares at $1.44 on 2025-05-14, bringing his holdings to 357,328 shares. The company is operating at a significant loss (net income of $-11.1M on revenue of $96.0M in the latest quarter) with annual revenue declining 1.2%. The stock is trading at $1.40, down -75.0% from its 52-week high of $5.60. Notably, 3 other insiders also purchased shares within the past 14 days, forming a cluster buy pattern. This synchronized buying activity by multiple executives during a period of sharp price weakness and negative earnings warrants attention to understand whether insiders possess information not yet reflected in public disclosures.